title: Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?
abstract: Findings within the current issue indicate that treatment with IPH2101 when used as a monotherapy in smoldering multiple myeloma, meant to enhance natural killer (NK) cell function through inhibitory KIR blockade, results in a surprising reduction of NK-cell function mediated through monocyte trogocytosis. The significance of these findings is discussed. Clin Cancer Res; 22(21); 5161-3. ©2016 AACRSee related article by Carlsten et al., p. 5211.
authors.affiliation: Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota. mille011@umn.edu mfelices@umn.edu.
authors.forename: Martin
authors.initials: M
authors.lastname: Felices
authors.affiliation: Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota. mille011@umn.edu mfelices@umn.edu.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Miller
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D009000:Monocytes / Q000276:immunology; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D054340:Receptors, KIR / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D054340:Receptors, KIR; C558235:IPH-2101